IP Library › Granted Patent US 12,559,540
Granted Patent B2
US 12,559,540 · App. 16/639,445 · Granted Feb 24, 2026

ApoM-Fc fusion proteins and uses thereof

Inventors: Timothy T. Hla (Wellesley, MA); Steven L. Swendeman (Cambridge, MA); Lois Smith (West Newton, MA)
Assignee: Children's Medical Center Corporation
C07K14/775A61K31/713A61P19/02A61P35/04C12N5/10C12N15/62C07K2319/02C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,559,540
App. No.
16/639,445
Granted
Feb 24, 2026
Kind
B2
Abstract

Provided herein are engineered fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG). In some embodiments, the ApoM-Fc fusion protein further comprises a signal peptide (e.g., IL-2 signal peptide) fused to the ApoM, allowing the fusion protein to be secreted once expressed recombinantly. Methods of using the ApoM-Fc fusion protein or the sponge variants in the treatment of various diseases or disorders are provided.

Claims (8)

1 . A fusion protein comprising an apolipoprotein M (ApoM) fused to a constant region (Fc) of an immunoglobulin (IgG), wherein the fusion protein comprises an amino acid sequence that is at least 99.5% identical to SEQ ID NO: 1.

2 . The fusion protein of claim 1 , wherein the ApoM comprises one or two amino acid substitutions at positions selected from the group consisting of positions T42, V46, I68, and M70 in SEQ ID NO: 5.

3 . The fusion protein of claim 1 , wherein the ApoM comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 5.

4 . The fusion protein of claim 2 , wherein the ApoM comprises the amino acid sequence of any one of SEQ ID NOs: 9-15.

5 . The fusion protein of claim 1 , wherein the fusion protein comprises the amino acid sequence of any one of SEQ ID NOs: 23-29.

6 . The fusion protein of claim 1 , comprising the amino acid sequence of SEQ ID NO: 1.

7 . A nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein of claim 1 .

8 . A method of producing a fusion protein, comprising culturing a cell comprising the nucleic acid molecule of claim 7 in a culturing media, under conditions that allow the fusion protein to express.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2021
From: HLA, TIMOTHY T.; SWENDEMAN, STEVEN L.; SMITH, LOIS
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 055097/0855 →
Continuity (2)
Provisional Application 62545629 · Aug 15, 2017
Related Publication 20210032310A1 · Feb 4, 2021
References Cited (49)
US 10870689B2 · Hla et al. · 2020 [cited by applicant]
US 20110178029A1 · Knudsen et al. · 2011 [cited by applicant]
US 20130195849A1 · Von Spreter et al. · 2013 [cited by applicant]
US 20130324701A1 · Williams et al. · 2013 [cited by applicant]
US 20140303086A1 · Hla et al. · 2014 [cited by applicant]
US 20160184458A1 · Heartlein · 2016 [cited by applicant]
US 20170360749A1 · Harijith et al. · 2017 [cited by applicant]
US 20190185545A1 · Hla et al. · 2019 [cited by applicant]
US 20210380665A1 · Hla et al. · 2021 [cited by applicant]
CN 1556409A · 2004 [cited by applicant]
CN 101557817A · 2009 [cited by applicant]
CN 102858985A · 2013 [cited by applicant]
CN 105175553A · 2015 [cited by applicant]
JP 2020531010A · 2020 [cited by applicant]
WO WO2006000448A2 · 2006 [cited by applicant]
WO WO2010049103A1 · 2010 [cited by applicant]
WO WO2012162392A1 · 2012 [cited by applicant]
WO WO2017031353A1 · 2017 [cited by applicant]
WO WO2018052615A1 · 2018 [cited by applicant]
WO WO2019035931A1 · 2019 [cited by applicant]
UniProt Database, Accession No. P01857, 20 pages (first available 1986) (Year: 1986). [cited by examiner]
NCBI Protein Blast Sequence Comparison, 1 page (performed on Apr. 8, 2022) (Year: 2022). [cited by examiner]
“Artificial”, Cambridge English Dictionary, available online at https://dictionary.cambridge.org/us/dictionary/english/artificial, 7 pages (accessed on Dec. 19, 2022) (Year: 2022). [cited by examiner]
Chen et al., Proc. Natl. Acad. Sci. 106:21783-21788 (2009) (Year: 2009). [cited by examiner]
Sioud et al., Molec. Ther. Methods Clin. Development 2:1-10 (2015) (Year: 2015). [cited by examiner]
Burg et al., Sphingosine 1-Phosphate Receptor 1 Signaling Maintains Endothelial Cell Barrier Function and Protects Against Immune Complex-Induced Vascular Injury. Arthritis Rheumatol. Nov. 2018;70(11):1879-1889. [cited by applicant]
Christoffersen et al., Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A. Jun. 7, 2011;108(23):9613-8. [cited by applicant]
Kaplan et al., Trail (Apo2 ligand) and Tweak (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol. Mar. 15, 2000;164(6):2897-904. [cited by applicant]
Snoek et al., Sphingolipids in Congenital Diaphragmatic Hernia; Results from an International Multicenter Study. PLoS One. May 9, 2016;11(5). [cited by applicant]
Swendemen et al., An engineered S1P chaperone attenuates hypertension and ischemic injury. Sci Signal. Aug. 15, 2017;10(492). [cited by applicant]
Wang et al., Immunoglobulin Fc domain fusion to Trail significantly prolongs its plasma half-life and enhances its antitumor activity. Mol Cancer Ther. Mar. 2014;13(3):643-50. [cited by applicant]
Wu et al., Pharmacokinetics of Peptide-Fc fusion proteins. J Pharm Sci. Jan. 2014;103(1):53-64. doi: 10.1002/jps.23783. Epub Nov. 27, 2013. [cited by applicant]
Yu et al., Immunoglobulin Fc domain fusion to apolipoprotein (a) kringle V significantly prolongs plasma half-life without affecting its anti-angiogenic activity. Protein Eng Des Sel. Jun. 2013;26(6):425-32. [cited by applicant]
Zauner et al., Glycoproteomic analysis of antibodies. Mol Cell Proteomics. Apr. 2013;12 (4):856-65. [cited by applicant]
[No Author Listed] GenBank Accession No. NP_061974.2. Apolipoprotein M Isoform 1. [cited by applicant]
[No Author Listed] GenBank Accession No. NP_061286.1. Apolipoprotein M Precursor. [cited by applicant]
Burg et al., Sphingosine-1 Phosphate Receptor-1-Mediated Endothelial Cell Barrier Function Protects Against Immune Complex-Induced Vascular Injury: A Potential Novel Therapeutic Target for SLE. Abstract 1790. 2017 ACR/A… [cited by applicant]
Christoffersen et al., The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem. Jul. 4, 2008;283(27):18765-72. [cited by applicant]
Andersson-Sjoland et al., ROS-induced endothelial stress contributes to pulmonary fibrosis through pericytes and Wnt signaling. Lab Invest. Feb. 2016;96(2):206-17. doi: 10.1038/labinvest.2015.100. Epub Sep. 14, 2015. [cited by applicant]
Green et al., The role of the endothelium in asthma and chronic obstructive pulmonary disease (COPD). Respir Res. Jan. 18, 2017;18(1):20. doi:10.1186/s12931-017-0505-1. [cited by applicant]
Zhaorigetu et al., Perturbations in Endothelial Dysfunction-Associated Pathways in the Nitrofen-Induced Congenital Diaphragmatic Hernia Model. J Vasc Res. 2018;55(1):26-34. doi: 10.1159/000484087. Epub Dec. 8, 2017. [cited by applicant]
Zhaorigetu et al., Perturbations in Endothelial Dysfunction-Associated Pathways in the Nitrofen-Induced Congenital Diaphragmatic Hernia Model. J Vasc Res. 2018;55(1):26-34. doi: 10.1159/000484087. Epub Dec. 8, 2017. Abs… [cited by applicant]
Chen et al., The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension. Am J Respir Crit Care Med. Nov. 1, 2014;190(9):1032-43. doi: 10.1164/rccm.201401-0121OC. [cited by applicant]
Gorshkova et al., Inhibition of serine palmitoyltransferase delays the onset of radiation-induced pulmonary fibrosis through the negative regulation of sphingosine kinase-1 expression. J Lipid Res. Aug. 2012;53(8):1553-… [cited by applicant]
Harijith et al., Sphingosine kinase 1 deficiency confers protection against hyperoxia-induced bronchopulmonary dysplasia in a murine model: role of S1P signaling and Nox proteins. Am J Pathol. Oct. 2013;183(4):1169-1182… [cited by applicant]
[No Author Listed], Conditions and Diseases: Bronchopulmonary Dysplasia from Johns Hopkins Medicine [online]. Accessed Jul. 12, 2024. www.hopkinsmedicine.org/health/conditions-and-diseases/bronchopulmonary-dysplasia. 7 … [cited by applicant]
[No Author Listed], Conditions and Diseases: Congenital Diaphragmatic Hernia (CDH) from Johns Hopkins Medicine [online]. Accessed Jul. 12, 2024. www.hopkinsmedicine.org/health/conditions-and-diseases/congenital-diaphrag… [cited by applicant]
Kho et al., Identification of dedifferentiation and redevelopment phases during postpneumonectomy lung growth. Am J Physiol Lung Cell Mol Physiol. Oct. 15, 2013;305(8):L542-54. doi: 10.1152/ajplung.00403.2012. Epub Aug.… [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/284,299 mailed May 20, 2025 and allowed claims as of May 20, 2025. [cited by applicant]